Related Experiment Video
Updated: May 24, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Metastatic Melanoma Treatment and Prophylaxis with S100A9-Targeting Cowpea Mosaic Virus Nanoparticles
Young Hun Chung1, Nicole F Steinmetz2,3,4,5,6,7
1Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
Abstract:
Metastatic cancer continues to be the main cause of cancer-related death, and new therapies must be continuously researched to eradicate these cancers. Immunotherapy aims to stimulate the patient's own immune system to recognize and eliminate tumors and metastatic sites. A particular powerful approach is the use of immunostimulatory agents to reprogram the tumor microenvironment from "cold" to "hot" to prime systemic antitumor immunity. Plant viruses have been investigated for this purpose because their repetitive coat protein structures with encapsidated nucleic acids render them potent immunostimulatory agents. In particular, the cowpea mosaic virus (CPMV) has been found to be a potent anticancer agent when injected intratumorally. However, metastatic cancers cannot be injected in situ, and therefore a systemically administered CPMV prevention and treatment option that is targeted to S100A9 was developed. S100A9 is an immunostimulatory protein that regulates metastatic cancer seeding and growth, thereby making it an attractive target for both prevention and treatment. Protocols for the production and characterization of S100A9-targeted CPMV nanoparticles are described and in vivo experiments that can be carried out to assess the efficacy of the S100A9-targeted CPMV nanoparticles in the prevention and treatment of metastatic melanoma to the lung are detailed. Finally, instructions for flow cytometry analysis of the innate immune cell composition within the lungs following S100A9-targeted CPMV administration are provided.
Insights
Systemic cowpea mosaic virus (CPMV) nanoparticles targeted to S100A9 show promise for preventing and treating metastatic cancer. This approach reprograms the tumor microenvironment to enhance the immune system's response against cancer cells.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Metastatic cancer is a leading cause of cancer mortality, necessitating novel therapeutic strategies.
- Immunotherapy, particularly reprogramming the tumor microenvironment, offers a promising avenue for cancer treatment.
- Plant viruses, like cowpea mosaic virus (CPMV), are potent immunostimulatory agents with anticancer potential.
Purpose of the Study:
- To develop a systemically administered, S100A9-targeted cowpea mosaic virus (CPMV) nanoparticle for metastatic cancer prevention and treatment.
- To evaluate the efficacy of these nanoparticles in preclinical models of metastatic melanoma.
- To detail protocols for nanoparticle production, characterization, and in vivo efficacy assessment.
Main Methods:
- Production and characterization of S100A9-targeted CPMV nanoparticles.
- In vivo experiments to assess nanoparticle efficacy in preventing and treating lung metastatic melanoma.
- Flow cytometry analysis of innate immune cell populations in the lungs post-administration.
Main Results:
- The study outlines methods for creating S100A9-targeted CPMV nanoparticles.
- Experimental protocols are detailed for evaluating nanoparticle efficacy against metastatic melanoma.
- Methods for analyzing immune cell responses in the lungs are provided.
Conclusions:
- S100A9-targeted CPMV nanoparticles represent a novel strategy for systemic cancer immunotherapy.
- This approach holds potential for both the prevention and treatment of metastatic cancers.
- Further investigation into the immune response modulation is warranted.
